Via News Knowledge File

Johnson & Johnson Services, Inc.

organization80% conf.·synced Sep 5, 2026

Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience

sourced metrics

1255

relationships

stated objectives

Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High

278.43USD

Sep 4, 2026reference only

Market Cap

663276390852USD

Sep 4, 2026reference only

Price 52 Week Low

174.16USD

Sep 4, 2026reference only

Stock Return Ytd

32.7%

Sep 4, 2026reference only

Stock Price

275.23USD

Sep 4, 2026reference only

Shares Outstanding

2409898597.0shares

Jul 17, 2026reference only

Revenue

25310000000.0USD

Jun 28, 2026reference only

Stockholders Equity

84971000000.0USD

Jun 28, 2026reference only

Cost Of Revenue

8051000000.0USD

Jun 28, 2026reference only

Total Assets

201061000000.0USD

Jun 28, 2026reference only

Gross Profit

17259000000.0USD

Jun 28, 2026reference only

Total Liabilities

116090000000.0USD

Jun 28, 2026reference only

Cash

20422000000.0USD

Jun 28, 2026reference only

Eps

2.27USD_per_share

Jun 28, 2026reference only

Net Income

5534000000.0USD

Jun 28, 2026reference only

Operating Cash Flow

2514000000.0USD

Mar 29, 2026reference only

Capex

1049000000.0USD

Mar 29, 2026reference only

Rd Expense

109000000.0USD

Dec 28, 2025reference only

Stated objectives

Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%

source

target: 93.5-93.9 billion USD stated

Improve adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs

source

target: ~300 bps improvement stated

Achieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%

source

target: >5% revenue growth stated

Achieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44

source

target: ~$11.44 adjusted EPS stated

Submit OTTAVA robotic surgical system for regulatory approval in the United States

source

target: Regulatory submission completed stated

Achieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026

source

by 2026-01-01 00:00:00stated

Improve MedTech growth and margins by completing the pending separation of the Orthopaedics franchise

source

stated

Strengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies

source

stated

Develop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem

source

stated

J&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026

source

target: higher than 2025 growth rates by 2026-01-01 00:00:00stated

Relationship graph · 1255 connections

Developed by

511

Competes with

133

subsidiary of

Covered by

Employs

Owns

acquired by

regulates

Developed by

Dual Energy THERMOCOOL SMARTTOUCH SF platform STELARA CAPLYTA TREMFYA TALVEY DARZALEX FASPRO OTTAVA Robotic Surgical System RYBREVANT Impella CP ICOTYDE Erda-iDRS Erdafitinib

Competes with

Abbott Laboratories Medtronic plc Boston Scientific

board member of

Joaquin Duato

headquartered in

New Brunswick, New Jersey Raritan, New Jersey

Employs

Joaquin Duato Jennifer Taubert John Reed Christopher Cutie

located in

Raynham, Massachusetts Spring House, Pennsylvania North Carolina

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →